

R1 R2 R3 PG0 PG1 Estagiário Tecnólogo PIBIC

Last Name - Ballalai

First Name - Priscilla

Middle - Luppi

Service (sector)

Tumors and Pathology

Nº CEP

Topical use of mitomycin C in the treatment of conjunctival intraepithelial neoplasia and squamous cell carcinoma: A preliminary study.

Author: Ballalai P.L., Gomes. J.A.P., Santos, M.S., Freitas, D., Erwenne, C.M., Rigueiro, M.

Purpose: To evaluate the efficacy and safety of the use of topical Mitomycin C (MMC) to treat conjunctival intraepithelial neoplasia (CIN) and squamous cell carcinoma (SCC) and the recurrent rates..

Methods: Prospective study with patients diagnosed with CIN or SCC by slit lamp examination and/or exfoliative cytology. Patients were treated with topical Mitomycin C 0,02% qid at most for 28 days. Fifteen days after completion of the treatment, exfoliative cytology was performed.

Results: Nine patients with CIN and three patients with SCC were enrolled. The mean follow-up was 7 months (range, 1 month to 13 months). Eight patients (89%) with CIN and 1 patient (33,4%) with SCC had total regression of the lesion. One patient (11%) with CIN and 2 patients with SCC (66,6%), had partial regression and were submitted to excisional surgery. Histological analysis showed no evidence of neoplastic cells. All patients remained lesion-free during the follow-up. Side effects (tearing, red-eye, punctate keratits, and epithelial defects) were transient and disappeared after discontinuation of the drug.

Conclusion: The preliminary results of this study suggest that the use of topical MMC to treat selected cases of CIN and SCC is safe and efficient, and showed no recurrence.